Additional chromosome abnormalities in chronic myeloid leukemia

Kaohsiung Journal of Medical Sciences

Volumn 27, Issue 2, 2011, Pages 49-54

  Hsiao, Hui Hua ^a,b   Liu, Yi Chang ^a,b   Tsai, Hui Jen ^a,b   Hsu, Jui Feng ^a   Yang, Wen Chi ^a,b   Chang, Chao Sung ^a,b   Lin, Sheng Fung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Additional chromosome abnormality; BCR ABL; Chronic myeloid leukemia; Variant Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; CYTOTOXIC AGENT; IMATINIB;

ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; KARYOTYPE 46,XX; KARYOTYPE 46,XY; KARYOTYPE 47,XXY; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA 1 CHROMOSOME; RETROSPECTIVE STUDY; SENESCENCE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 79952296972     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.kjms.2010.09.001     Document Type: Article

References (34)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:1-16.
3. Bartram C, DE Klein A, Hagermeiger A. Translocation of c-abl oncogene correlates with the presence of the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1984;306:277-80. (Pubitemid 14232360)
4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
5. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 2001;61:2343-55. (Pubitemid 32691130)
6. Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 2002;21:8652-67. (Pubitemid 36084197)
7. Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 2003;121:419-27. (Pubitemid 36628333)
8. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 1993;11:11-5. (Pubitemid 23274129)
9. Reddy KS, Sulcova V. A FISH study of variant Philadelphia rearrangements. Cancer Genet Cytogenet 2000;118:121-31. (Pubitemid 30169213)
10. Naumann S, Decker HJ. Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia. Cancer Genet Cytogenet 2003;147:18-22. (Pubitemid 37324342)
11. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-84. (Pubitemid 26327486)
12. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? Blood 1991;78:1155-61.
13. Emilia G, Luppi M, Marasca R, Torelli G. Relationship between BCR/ABL fusion proteins and leukemia phenotype. Blood 1997;89:3889-90.
14. Emilia G, Luppi M, Ferrari MG, Temperani P, Marasca R, Giacobbi F, et al. Chronic myeloid leukemia with thrombocythemic onset may be associated with different BCR/ABL variant transcripts. Cancer Genet Cytogenet 1998;101:75-7. (Pubitemid 28071365)
15. Prejzner W. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia. Med Sci Monit 2002;8:193-7.
16. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. (Pubitemid 36302244)
17. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003;17:1013-34. (Pubitemid 36722231)
18. Johannson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002;107:76-94. (Pubitemid 34264171)
19. Deininger MWN. Cytogenetic studies in patients on imatinib. Semin Hematol 2003;40:50-5. (Pubitemid 36687160)
20. Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T. Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia. Leuk Lymphoma 2005;46:357-66. (Pubitemid 40220394)
21. Farag SS, Ruppert AS, Mrozek K, Carroll AJ, Pettenati MJ, Le Beau MM, et al. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-a: a Cancer and Leukemia Group B study. Int J Oncol 2004;25:143-51.
22. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809-20. (Pubitemid 44394987)
23. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010-22. (Pubitemid 38685338)
24. Sokal JE, Baccarani M, Tura S, Fiacchini M, Cervantes F, Rozman C, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 1985;66:1352-7. (Pubitemid 16194698)
25. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. J Natl Cancer Inst 1998;90:850-8. (Pubitemid 28280552)
26. Passweg JR, Walker I, Sobocinski KA, Klein KA, Horowitz MM, Giralt SA, et al. Validation and extension of the EBMT risk score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004;125:613-20. (Pubitemid 38747964)
27. Jacob RT, Gayathri K, Surath A, Rao DR. Cytogenetic profile of chronic myeloid leukemias. Indian J Cancer 2002;39:61-5. (Pubitemid 39663710)
28. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51.
29. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004;126:187-96.
30. Herens C, Tassin F, Lemaire V, Beguin Y, Collard E, Lampertz S, et al. Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 2000;110:214-6. (Pubitemid 30625611)
31. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98:1732-8.
32. Angstreich GR, Smith BD, Jones RJ. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant. Curr Opin Oncol 2004;16:95-9. (Pubitemid 38402519)
33. Lange T, Bumm T, Mueller M, Otto S, Al-Ali HK, Grommisch L, et al. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia 2005;19:1262-9.
34. Sausville EA. Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard? Lancet 2003;361:1400-1.